You are here
Efficacy and Safety for Diabetes Specialists
for Diabetes Specialists
The purpose of this course is to learn how the efficacy and safety of basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy surpasses that of the individual components. Participants will learn how to identify patients who are most likely to benefit from this combination. Practical considerations will be discussed, including tips on how to best manage patients during treatment with basal insulin–GLP-1 receptor agonist combination therapy.
Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk